RedHill Biopharma Ltd. ("RDHL") Corporate Presentation March 2020 Forward Looking Statement This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no re ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q3 2019 Earnings Conference Call November 19, 2019 8:30 AM ET | --- | |---------------------------------------------------------------------------| | | | Company Participants | | Dror Ben-Asher - CEO | | Micha Ben-Chorin - CFO | | Gilead Raday - COO | | Rick Scruggs - COO, U.S. Operations Guy Goldberg - Chief Business Officer | | Conference Call Participants | | Jackson Harvey - Nomura/Instinet | | Steve Brozak - WBB | | Scott Henry - ROTH Capital Partners | | Matt Kapla ...

RedHill Biopharma Ltd. ("RDHL") Corporate Presentation September 2019 Disclaimer and Forward Looking Statements No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no representation or warranty is given, and the Company has no responsibility, as to the achievement or reasonableness of any forecasts, estimates, or statements as to prospects contained or referred to in th ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q2 2019 Earnings Conference Call July 23, 2019 8:30 AM ET Company Participants Guy Goldberg - Chief Business Officer Dror Ben-Asher - Chief Executive Officer Micha Ben-Chorin - Chief Financial Officer Gilead Raday - Chief Operating Officer Rick Scruggs - Chief Operating Officer, U.S. Operations Conference Call Participants Christopher Marai - Nomura Matt Kaplan - Ladenburg Thalmann Scott Henry - Roth Capital Steve Brozak - WBB Robin Garner - LifeSci Capital Ed Woo - Asce ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Alexandra Okmian - Investor Relations Dror Ben-Asher - Chief Executive Officer Micha Ben Chorin - Chief Financial Officer Gilead Raday - Chief Operating Officer Guy Goldberg - Chief Business Officer Conference Call Participants Christopher Marai – Nomura | Instinet Stephen Brozak - WBB Securities, LLC Matthew Kaplan - Ladenburg Thalmann & Co. Inc. Jonas Peciulis - Edison Investment Research Edwa ...

RedHill Biopharma Ltd. ("RDHL") Corporate Presentation April 2019 Disclaimer and Forward Looking Statements No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no representation or warranty is given, and the Company has no responsibility, as to the achievement or reasonableness of any forecasts, estimates, or statements as to prospects contained or referred to in this p ...

RedHill Biopharma Ltd. ("RDHL") Corporate Presentation March 2019 Disclaimer and Forward Looking Statements No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no representation or warranty is given, and the Company has no responsibility, as to the achievement or reasonableness of any forecasts, estimates, or statements as to prospects contained or referred to in this p ...

Financial Data and Key Metrics Changes - Net revenues for 2018 were $8.4 million, up from $4 million in 2017, marking a 110% increase [6] - Gross profit increased to $5.5 million in 2018 from $1.9 million in 2017, with gross margin rising from 47% to 66% [6] - Operating loss decreased to $39.3 million in 2018 from $52 million in 2017, a reduction of 24% [10] - Net cash used in operating activities was $34.5 million in 2018, down from $44.8 million in 2017, a reduction of 23% [11] - Cash balance as of December 31, 2018, was $53.2 million, compared to $46.2 million at the end of 2017 [12] Business Line Data and Key Metrics Changes - Research and development expenses decreased to $24.9 million in 2018 from $33 million in 2017, primarily due to the completion of Phase 3 studies [7] - Selling, marketing, and business development expenses were $12.5 million in 2018, only 4% higher than in 2017 [9] - General and administrative expenses were approximately $7.5 million in 2018, a 6% decrease from 2017 [10] Market Data and Key Metrics Changes - The global market for H. pylori treatment was estimated at nearly $5 billion in 2018, with H. pylori affecting over 50% of the world's adult population [19] - The medical need for effective H. pylori treatments is increasing due to rising antibiotic resistance, with current therapies failing approximately 30% of patients [20][21] Company Strategy and Development Direction - The company is focused on the U.S. gastrointestinal market and aims to launch TALICIA for H. pylori infection, with a potential NDA filing in the first half of 2019 [4][18] - RedHill is pursuing pharma out-licensing partnerships and acquisitions to enhance its product portfolio and achieve profitability more rapidly [14] - The company plans to establish a strong presence in the U.S. GI community and is preparing for the potential launch of TALICIA, with or without a partner [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential launch of TALICIA, which could become the new standard of care for H. pylori treatment if approved by the FDA [18] - The company is optimistic about growth in 2019, expecting to secure additional products to enhance its sales force offerings [70] - Management highlighted the importance of market access as a key learning point and is focusing efforts on this area [77] Other Important Information - The company reported strong results from the Phase 3 study of RHB-104 for Crohn's disease, meeting both primary and key secondary endpoints [22][23] - Discussions with potential pharmaceutical partners for RHB-104 are ongoing, with management optimistic about the data impressing potential partners [37] Q&A Session Summary Question: When should we expect a readout of the pivotal trial for RHB-204? - The company expects roughly one year for enrollment and plans to file the NDA shortly after the last patient completes treatment [34] Question: Can you discuss the marketed products and their performance in Q4? - Management anticipated fluctuations in Q4 due to technical issues affecting net sales prices but expects Q1 to be back on track [41][42] Question: What are the pre-launch costs for TALICIA in 2019? - The company is already incurring pre-launch costs related to marketing, positioning, and supply chain preparations [45] Question: How do you compare the opportunities with RedHill to Salix? - The new head of U.S. operations has significant experience from Salix, which is expected to help launch TALICIA effectively [55] Question: What are the next steps for the NDA filing for TALICIA? - The company plans to meet with the FDA soon and hopes to submit the NDA immediately thereafter [63] Question: Will the launch of TALICIA impact the sales of other drugs? - Currently, the company has the capacity to add products to its sales team without detracting from existing operations [98]